Liraglutide

Liraglutide

CAT N°: 24727
Price:

From 140.00 119.00

Liraglutide is a potent agonist of the glucagon-like peptide 1 (GLP-1) receptor and a synthetic derivative of GLP-1 (7-37) (Item No. 24887) that contains a palmitic acid group.{43159} It increases cAMP accumulation in CHO cells expressing the human GLP-1 receptor (EC50 = 61 pM). Liraglutide (100-1,000 nM) inhibits cytokine- and free fatty acid-induced apoptosis of primary neonatal rat pancreatic ?-cells in vitro by greater than 95 and 50%, respectively, effects that are blocked by the GLP-1 receptor antagonist exendin-3 (9-39) (Item No. 19890) and the PI3 kinase inhibitor wortmannin (Item No. 10010591).{43160} In a rat model of obesity induced by supplemental dietary candy, liraglutide (0.2 mg/kg, s.c., twice per day) decreases calorie intake, shifts food preference to a higher ratio of chow to candy, reverses weight and fat gains, and increases insulin sensitivity.{43161} Formulations containing liraglutide have been used as adjuncts in the treatment of type 2 diabetes and for chronic weight management in overweight or obese adults.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • L-histidyl-L-alanyl-L-?-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-?-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-?-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-?-glutamyl]-L-lysyl-L-?-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-glycine
  • Correlated keywords
    • Victoza NNC 90-1170 NNC901170 901170 NNC90 NN2211 GLP1 FA Liraglutida Saxenda Liraglutidium
  • Product Overview:
    Liraglutide is a potent agonist of the glucagon-like peptide 1 (GLP-1) receptor and a synthetic derivative of GLP-1 (7-37) (Item No. 24887) that contains a palmitic acid group.{43159} It increases cAMP accumulation in CHO cells expressing the human GLP-1 receptor (EC50 = 61 pM). Liraglutide (100-1,000 nM) inhibits cytokine- and free fatty acid-induced apoptosis of primary neonatal rat pancreatic ?-cells in vitro by greater than 95 and 50%, respectively, effects that are blocked by the GLP-1 receptor antagonist exendin-3 (9-39) (Item No. 19890) and the PI3 kinase inhibitor wortmannin (Item No. 10010591).{43160} In a rat model of obesity induced by supplemental dietary candy, liraglutide (0.2 mg/kg, s.c., twice per day) decreases calorie intake, shifts food preference to a higher ratio of chow to candy, reverses weight and fat gains, and increases insulin sensitivity.{43161} Formulations containing liraglutide have been used as adjuncts in the treatment of type 2 diabetes and for chronic weight management in overweight or obese adults.

We also advise you